

Inhibition of Apolipoprotein(a) Synthesis by Farnesoid X Receptor and Fibroblast Growth Factor 15/19 A Step Toward Selective Lipoprotein(a) Therapeutics

Sergio Fazio, MacRae F. Linton

Lipoprotein(a), or Lp(a), is a plasma lipoprotein that accumulates in concentrations ranging from undetectable to as high as 200 mg/dL, mostly depending on the synthesis rate of its unique protein, apo(a), which consists of multiple repetitions of kringle IV, type 2 of plasminogen.¹ Additionally, plasma levels of Lp(a) are inversely proportional to the size of the apo(a) isoform, which is genetically determined.² Considering that cholesterol represents about one fifth of the particle, Lp(a) can be equivalent to an extra 40 mg/dL of low-density lipoprotein (LDL) cholesterol in some individuals. The complex is the result of a covalent association between apoB100 and the function-free apo(a). The size of this lipoprotein ranges from that of a large high-density lipoprotein (HDL) to that of a small remnant depending on its triglyceride content. It is an apoB-containing lipoprotein and therefore viewed as an atherogenic particle. Because apo(a) does not form Lp(a) in murine plasma, development of a transgenic mouse model has required the concomitant expression of human apo(a) and apoB100.³ Apo(a) binds via a single disulfide bridge to the carboxyl-terminus of apoB100 and thus cannot associate with chylomicrons, which only contain apoB48.⁴ Also, apo(a) preferentially binds apoB100 of LDL-sized particles, although the linkage between the 2 proteins is likely to take place on the surface of hepatocytes, which produce exclusively VLDL-sized particles.⁵ On the clearance front, Lp(a) does not bind to the LDL receptor, and only modest increases in Lp(a) levels are seen in patients with familial hypercholesterolemia.⁶ This means that cholesterol-lowering agents acting more or less directly via upregulation of the LDL receptor (statins, resins, and cholesterol absorption inhibitors) have modest to no effects or may even raise plasma Lp(a) levels.⁷⁻⁹ Other agents, such as fibrates and niacins, share similar lipid-modulating effects (decreasing triglycerides, increasing HDL cholesterol) but show diverging effects on Lp(a) levels, which may be increased modestly by fenofibrate¹⁰ and decreased significantly by niacin.¹¹ The mechanism of action of niacin on Lp(a) is not defined, but is likely related to reduced secretion of apoB-containing lipoproteins by the liver. This notion is confirmed by emerging therapies that directly regulate hepatic

apoB output, such the apoB antisense mipomersen and the liver-specific thymimetic eprotirome, both of which lower Lp(a) levels.^{12,13}

See accompanying article on page 1220

Because production of apo(a) is the critical step in the assembly and plasma accumulation of Lp(a), a logical approach to targeting this lipoprotein pharmacologically would be via inhibition of the synthesis of this apparently unnecessary protein. No available drugs are known to act on this mechanism. Even though Lp(a) was discovered nearly 50 years ago, the debate on whether it represents a risk factor for cardiovascular disease is still ongoing, but consensus is finally mounting up for its role in the disease process, necessity of screening, and recommendation of therapeutic targeting.¹⁴ Because of the absence of agents that exclusively and significantly modulate Lp(a) levels, there is no clinical trial information on the importance of lowering Lp(a) levels to reduce cardiovascular events. However, Maher et al¹⁵ in 1995 published evidence showing that the excess cardiovascular risk attributable to elevated Lp(a) levels was nearly eliminated by lowering LDL below 100 mg/dL. This was interpreted by many practitioners as a recommendation to use Lp(a) simply as a marker to decide the level of LDL lowering necessary to control risk. It is undeniable, however, that some high-risk patients in practice present with extremely elevated Lp(a) levels as the most prominent risk factor, and it is not known whether aggressive reduction of Lp(a) would be of benefit in these individuals. Recent population data have given what many consider the final confirmation of the importance of apo(a) and Lp(a) in cardiovascular risk attribution.^{16,17} Therefore, more emphasis is currently being placed on determining Lp(a) levels as part of cardiovascular risk profiling, often leading to management of inappropriately elevated levels (>50 mg/dL of particle mass).¹⁴ Niacin, the only commonly used lipid-lowering agent that reduces Lp(a) levels, is currently being questioned as an appropriate agent for high-risk subjects given the negative results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial, where it failed to convey additional risk reduction to coronary artery disease patients already taking statin, alone or with ezetimibe.¹⁸ In this National Institutes of Health cosponsored trial, niacin was used with the intent of increasing HDL cholesterol levels in subjects at LDL goal, and therefore the lack of clinical effects is currently being attributed to either an ineffective HDL modulation by niacin or the general futility of raising HDL in high-risk individuals with LDL already at goal. Because niacin also reduced Lp(a) levels by 25%, it may

From the Division of Cardiovascular Medicine, Atherosclerosis Research Unit, Vanderbilt University Medical Center, Nashville, TN.

Correspondence to Sergio Fazio, MD, PhD, Division of Cardiovascular Medicine, Vanderbilt University, Room 383 PRB, 2220 Pierce Ave, Nashville, TN. E-mail sergio.fazio@vanderbilt.edu
(*Arterioscler Thromb Vasc Biol.* 2012;32:1060-1062.)

© 2012 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at <http://atvb.ahajournals.org>
DOI: 10.1161/ATVBAHA.112.245571

be inferred that this maneuver also fails to produce benefits. It has to be noted, however, that in the AIM-HIGH trial the median Lp(a) level was low (<20 mg/dL).

In the study by Chennamsetty et al¹⁹ published in this issue of *Arteriosclerosis, Thrombosis, and Vascular Biology*, evidence is presented for a negative regulation of apo(a) synthesis that could eventually be exploited for development of therapeutics to reduce Lp(a) levels. In a recent report, the same group of investigators showed that bile acid strongly inhibits apo(a) synthesis.²⁰ Patients with biliary obstruction and plasma bile acid levels 10 times above normal had Lp(a) levels either undetectable or inappropriately low for the apo(a) isoform. Lp(a) levels increased by nearly 10-fold on average after correction of the biliary obstruction. It should be noted that a similar observation was previously made with children affected by Alagille syndrome, where the inappropriate maturation of intrahepatic biliary canaliculi causes a significant elevation in plasma bile acid levels, and where extreme hypercholesterolemia is accompanied by low or undetectable Lp(a) levels.²¹ In their previous paper, the authors also showed that ligation of the common biliary duct in transgenic mice expressing human apo(a) reduced the synthesis of this protein by nearly 90%. This effect was repeated by cholic acid treatment, thus suggesting a role for farnesoid X receptor (FXR), a transcription factor that binds and gets activated by bile acids. Indeed, the effect of cholic acid on apo(a) synthesis was not noted in FXR null mice. The authors were able to identify the direct repeat 1 element (nucleotides -826 to -814) of the apo(a) gene promoter as a negative FXR response element. The inhibitory effect of FXR was attributable to competitive direct repeat 1 binding with hepatocyte nuclear factor 4 α , which instead promotes transcription of the apo(a) gene. Although impressive, the results also showed that the inhibitory effect of cholic acid on apo(a) synthesis could not be attributed exclusively to FXR competition with hepatocyte nuclear factor 4 α at the direct repeat 1 element. Because FXR also transactivates mouse fibroblast growth factor (FGF)15 and its human ortholog, FGF19, an intestinal protein that signals transcriptional repression of bile acid biosynthesis,²² the authors conducted another series of experiments to complete this promising story.

In the current paper, the investigators show that FGF19 binds to fibroblast growth factor receptor 4 and activates a signaling cascade involving the MAPK/ERK1/2 pathway leading to suppression of apo(a) transcription via nuclear displacement of phosphorylated Elk-1 and binding to Ets-1, a negative control element (-1630 to -1615) in the human apo(a) gene promoter. FGF19 treatment of primary hepatocytes from human apo(a) transgenic mice reduced accumulation of apo(a) in the medium by nearly 50%. Injection of FGF19 in mice produced a similar effect on liver mRNA and plasma levels of apo(a). An acute knockdown of fibroblast growth factor receptor 4, the receptor for FGF19, significantly reduced the inhibitory effect on apo(a) transcription. After showing that FGF19 causes phosphorylation of ERK1/2, both cloning experiments and in silico analysis suggested the Ets-1 element as the binding site for an inhibitory effect. Elk-1 was then an obvious choice, because this nuclear factor is a substrate for ERK1/2 and is known to bind Ets-1. Proof of this involvement comes

from a chromatin precipitation experiment showing binding of Elk-1 to the Ets-1 element of the apo(a) promoter after incubation with FGF19.

Although obtained in an artificial setting using human proteins in the mouse model, these results are novel and relevant to development of therapeutics, as they forecast the possibility that natural molecules such as bile acids or novel FXR and FGF19 agonistic agents may be used to decrease apo(a) synthesis and regulate plasma Lp(a) levels. However, a more informed expectation for the clinical applicability of such an intervention would obviously derive from human studies. Since FXR agonists have been tested and may be marketed for treatment of subjects with primary biliary cirrhosis (<http://clinicaltrials.gov/ct2/show/NCT00550862>), this patient population is unlikely to yield information on Lp(a), as its levels should be depressed by the condition and further suppressed by treatment. We encourage an evaluation of Lp(a) level changes in existing clinical trial data sets of subjects taking either bile acids for treatment or prevention of cholelithiasis, or bile acid binding resins for lipid or glucose management.

Sources of Funding

The authors were partially supported by National Institutes of Health grants HL106845, HL 57986 (to Sergio Fazio), and HL086988 and HL105375 (to MacRae F. Linton).

Disclosures

None.

References

1. Utermann G. The mysteries of lipoprotein(a). *Science*. 1989;246:904-910.
2. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. *Curr Opin Lipidol*. 1999;10:225-236.
3. Linton MF, Farese RV Jr, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). *J Clin Invest*. 1993;92:3029-3037.
4. McCormick SP, Linton MF, Hobbs HH, Taylor S, Curtiss LK, Young SG. Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein. *J Biol Chem*. 1994;269:24284-24289.
5. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. *J Biol Chem*. 1994;269:28716-28723.
6. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 2000;20:522-528.
7. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. *Atherosclerosis*. 1982;44:61-71.
8. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. *Heart*. 2003;89:893-896.
9. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. *Am J Cardiol*. 2000;85:350-353.
10. Ko HS, Kim CJ, Ryu WS. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. *J Cardiovasc Pharmacol*. 2005;46:405-411.
11. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. *J Intern Med*. 1989;226:271-276.
12. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim

- JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010;375:998–1006.
13. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. *N Engl J Med*. 2010;362:906–916.
 14. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarencu P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31:2844–2853.
 15. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). *JAMA*. 1995;274:1771–1774.
 16. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. 2009;361:2518–2528.
 17. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA*. 2009;301:2331–2339.
 18. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365:2255–2267.
 19. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. *Arterioscler Thromb Vasc Biol*. 2012;32:1220–1227.
 20. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM. Farnesoid X receptor represses hepatic human APOA gene expression. *J Clin Invest*. 2011;121:3724–3734.
 21. Gottrand F, Clavey V, Fruchart JC, Farriaux JP. Lipoprotein pattern and plasma lecithin cholesterol acyl transferase activity in children with Alagille syndrome. *Atherosclerosis*. 1995;115:233–241.
 22. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. *Science*. 2011;331:1621–1624.

KEY WORDS: intravascular ultrasound/Doppler

Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

Inhibition of Apolipoprotein(a) Synthesis by Farnesoid X Receptor and Fibroblast Growth Factor 15/19: A Step Toward Selective Lipoprotein(a) Therapeutics

Sergio Fazio and MacRae F. Linton

Arterioscler Thromb Vasc Biol. 2012;32:1060-1062

doi: 10.1161/ATVBAHA.112.245571

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2012 American Heart Association, Inc. All rights reserved.

Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/content/32/5/1060>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:

<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:

<http://atvb.ahajournals.org/subscriptions/>